[Expression Level and Function of UBE2QL1 in Multiple Myeloma]

To investigate the expression level of UBE2QL1 in multiple myeloma (MM) and its correlation with disease progression and prognosis, as well as to elucidate the biological role of UBE2QL1 in MM through in vitro cell experiments.

Bioinformatics analysis was used to explore the expression level of UBE2QL1 in MM and its impact on prognosis. Concurrently, a polyclonal antibody against UBE2QL1 was synthesized, and its specificity was confirmed through mass spectrometry. The expression level of UBE2QL1 in MM cell lines and primary bone marrow samples was validated using qRT-PCR and Western blot, followed by comparative analysis with the corresponding clinical data. Subsequently, the UBE2QL1 gene was knocked down in the MM cell lines NCI-H929 and MM.1S. to verify its regulatory effects on MM cell functions.

Analyses based on the Hemap, DepMap (CCLE), and GEO databases revealed that UBE2QL1 was highly expressed in MM, and its expression level was closely associated with disease progression and poor prognosis.In vitro experiments further confirmed the elevated expression of UBE2QL1 in MM cell lines and primary bone marrow samples from patients, showing a positive correlation with the proportion of plasma cells. Knockdown of UBE2QL1 in MM cell lines inhibited cell proliferation, promoted cell apoptosis, and improved cellular sensitivity to widely used therapeutic agents, including bortezomib, carfilzomib, and lenalidomide.

UBE2QL1 is highly expressed in MM and is closely associated with adverse disease progression and poor prognosis. Knockdown of UBE2QL1 in vitro can effectively inhibit MM cell proliferation, promote apoptosis, and enhance cellular sensitivity to therapeutic agents. Monitoring the expression level of UBE2QL1 may help to more accurately assess the prognosis of MM patients and provide a reference for therapeutic decision-making.